Stocks and Investing Stocks and Investing
Thu, March 24, 2022
Wed, March 23, 2022

Brian Skorney Maintained (VRTX) at Buy and Held Target at $240 on, Mar 23rd, 2022


Published on 2024-10-27 20:10:22 - WOPRAI, Brian Skorney
  Print publication without navigation


Brian Skorney of Baird, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $240 on, Mar 23rd, 2022.

Brian has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Wednesday, February 16th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Brian


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $265 on, Wednesday, December 22nd, 2021
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021
Contributing Sources